Search Results
Your search for it matches 15756 pages
Showing 10451 - 10500Young Women Require Formal Assessment to Identify Breast Cancer Risk
Half of the young women presenting to an academic surgical breast practice would qualify for mammography screening starting at age 40. According to the newly updated guidelines, these young at-risk women may be missed, researchers reported at the 2016 American Society of Breast Surgeons (ASBS)...
ODAC Advises the FDA to Wait for Phase III Results for Rociletinib in Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) met April 12 to consider a New Drug Application by Clovis Oncology for rociletinib, an investigational therapy for epidermal growth factor receptor (EGFR)-mutated non–small cell lung cancer (NSCLC) in patients...
Venetoclax for Previously Treated Chronic Lymphocytic Leukemia With 17p Deletion
On April 11, 2016, venetoclax (Venclexta) was approved for treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by a U.S. Food and Drug Administration (FDA)-approved test, who have received at least one prior therapy.1,2 The accelerated approval was based...
FDA Grants Selumetinib Orphan Drug Designation for Adjuvant Treatment of Differentiated Thyroid Cancer
Earlier this month, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for the investigational MEK1/2 inhibitor selumetinib for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer. Selumetinib inhibits the MEK...
10 Things You Need to Know About the Cancer MoonShot 2020 Program
In the fall of 2015, Vice President Joe Biden called for a “moonshot” to cure cancer. In his final State of the Union Address on January 12, 2016, President Barack Obama reemphasized that goal, stating, “Let’s make America the country that cures cancer once and for all.” To achieve that goal, the...
Expect Questions About the New Rule on E-Cigarettes
“There are a lot of myths around new and emerging tobacco products, including e-cigarettes, and unfortunately, the biggest misconception is that these products are fairly or entirely harmless and risk-free,” Alexander V. Prokhorov, MD, PhD, said in an interview with The ASCO Post about a new...
Expert Point of View: Louis M. Weiner, MD
“These gene fusions that drive malignant processes in certain cancers are good targets for cancer therapy. These targets can be potentially disabled [by targeted therapy],” said Louis M. Weiner, MD, Director of the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, who moderated a ...
New FDA Rule Prohibits Sale of E-Cigarettes to Anyone Under Age 18 and Requires Warning Labels
A new rule extending U.S. Food and Drug Administration (FDA) oversight to all tobacco products, including electronic cigarettes (e-cigarettes), and banning the sale of these products to anyone under the age of 181 was hailed as a major advanced by many leaders of medical and health organizations....
Expert Point of View: Mayer Fishman, MD, PhD
“This was a difficult study to conduct. It required 13 centers in 8 countries over 3 years to recruit these patients—that’s about 1 patient per site per year,” said Mayer Fishman, MD, PhD, of Moffitt Cancer Center in Tampa, Florida. “It’s an important study, because these patients are typically...
Crizotinib Active in Orphan Kidney Malignancy
Crizotinib (Xalkori) achieved overall and durable responses in advanced inoperable papillary renal cell carcinoma type 1 characterized by somatic MET mutations, according to an investigator-initiated trial conducted by the European Organization for Research and Treatment of Cancer (EORTC).1 “To...
The 10-Year Club
The following essay by Maurie Markman, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. What’s...
Highlights From the 2016 AACR Annual Meeting
This year’s Annual Meeting of the American Association for Cancer Research (AACR) featured outstanding research in the field of cancer, as well as an inspiring talk by Vice President Joe Biden (see the May 10 issue of The ASCO Post). Here are some summaries of studies that warrant attention; they...
Cabozantinib in Advanced Renal Cell Carcinoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 25, 2016, a tablet formulation of cabozantinib...
Cases of Mixed Hepatocellular Carcinoma–Cholangiocarcinoma Emerging
Combined hepatocellular carcinoma–cholangiocarcinoma is a histopathologically distinct tumor for which no formal treatment guidelines exist. It is also a malignancy that is being diagnosed more often, according to researchers from Mount Sinai Beth Israel Medical Center, New York, who reported...
White Knuckling
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Fitness: Can Exercise Lengthen Survival in Patients With Cancer?
Integrative Oncology is guest edited by Barrie R. Cassileth, MS, PhD, of Memorial Sloan Kettering Cancer Center, New York. Regular physical activity has long been associated with decreased risk of disease, including many types of cancer. Such benefits may translate into increased life expectancy...
Ushering in a New Era in Personalized Medicine
When Waun Ki Hong, MD, and his pregnant wife, Mihwa, made the journey from Korea to Manhattan in 1970, he had just $451 in his wallet, and the only job he could get was as an intern in Bronx-Lebanon Hospital Center, a community hospital in the Bronx. The work was grueling—24-hour shifts every 2...
CancerLinQ Completes Agreements With 36 ‘Vanguard’ Practices
CancerLinQ LLC announced on April 21 that it has completed agreements with 36 oncology practices from around the country to begin implementing CancerLinQ™, the groundbreaking health information technology platform that will harness big data analytics to help oncologists rapidly improve high-quality ...
Breast Cancer Research Foundation: Revitalizing Academic Research in Breast Cancer Through Drug Research Collaborative
When Evelyn H. Lauder was diagnosed with breast cancer in 1989, she became a vocal spokesperson for women’s health, and in 1993, along with Larry Norton, MD, now Deputy Physician-in-Chief for Breast Cancer Programs and Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan...
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2016 Guidelines
In 1996, the National Comprehensive Cancer Network (NCCN®) published its first set of Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), covering eight tumor types. The NCCN Guidelines® are now published for more than 60 tumor types and topics. Some of the key updates for 2016 were...
Recent Reports on Treatment for Leukemias, Sinusoidal Obstruction Syndrome, and Graft-vs-Host Disease
In this installment of Hematology Expert Review, I will summarize five studies from the recent literature addressing important questions about leukemias and their treatment, anticoagulant therapy with the new agent defibrotide (Defitelio), and the use of antilymphocyte globulin to prevent chronic...
How Immunotherapy Is Revolutionizing Cancer Care
More than 100 years after William B. Coley, MD, used bacterial toxins to goad the immune system into recognizing cancer cells as foreign to the body and mount an immune response to go after and kill them, the recognition of immunotherapy as a powerful anticancer therapy is finally being...
Expert Point of View: Padmanee Sharma, MD, PhD
“When we treat our patients, overall survival is the gold standard. We are all waiting for phase III overall survival data from CheckMate 067,” said formal discussant Padmanee Sharma, MD, PhD, Professor; Scientific Director of the Immunotherapy Platform; and Co-Director of the Parker Institute for ...
Maximizing Cancer Cure: How Do We Get There?
Is cancer really “curable,” and if so, how? For a “Cancer Dialogue” held during the 2016 American Association of Cancer Research (AACR) Annual Meeting, half a dozen stellar participants from the research, industry, regulatory, and advocacy communities convened to debate the topic. The ASCO Post was ...
Expert Point of View: Shaji K. Kumar, MD and Sergio A. Giralt, MD
Two experts in multiple myeloma commented on the EMN02/HO95 MM trial for The ASCO Post: Shaji K. Kumar, MD, Professor of Hematology at the Mayo Clinic, Rochester; and Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, New York. Both...
The Arrival of Generic Imatinib Into the U.S. Market: An Educational Event
Imatinib mesylate (Gleevec), a Bcr-Abl tyrosine kinase inhibitor, is approved therapy for chronic myeloid leukemia (CML) in the United States. Imatinib is a miraculous drug that results in a normal functional lifespan in most patients with CML who can afford and comply with the treatment and who ...
Pembrolizumab Survival Benefit Proves Durable in Patients With Advanced Melanoma
With new immunotherapies available for the treatment of advanced melanoma, an important question is how best to combine and sequence them. Long-term follow-up from the KEYNOTE-001 trial suggests that pembrolizumab (Keytruda) can improve survival in newly diagnosed patients and in those treated...
What ASCO Can Do for You—and for Our Patients
This is an exciting time to be an oncologist. I often say I wish I were 30 again and just starting out in my oncology career. Never before have we had such sophisticated technology for evaluation of the tumor or such a potent arsenal of targeted and effective therapies to treat cancer. Further, the ...
Oncology and Diplomacy in the Middle East
The Middle East is a vast region comprised largely of developing nations with complicated sociopolitical challenges, violent internecine disputes, and deeply fragmented health-care systems. Not surprisingly, the region’s suboptimal health care contributes to the late diagnosis and poor survival...
A Psychotherapist’s Approach to End-of-Life Care
BookmarkTitle: Dying: A TransitionAuthor: Monika Renz, PhD; translated by Mark Kyburz and John PeckPublisher: Columbia University PressPublication date: October 2015Price: $38.00; hardcover, 176 pages The night before Julius Caesar was assassinated, he had dinner with his friend Marcus...
In Celebration of a Remarkable Career at ASCO
In March, ASCO announced that Allen S. Lichter, MD, FASCO, was stepping down as Chief Executive Officer (CEO) at the end of June, ending his 10-year tenure as head of the Society and the Conquer Cancer Foundation of ASCO. Clifford A. Hudis, MD, FACP, Chief of Breast Medicine Service and Vice...
Expert Point of View: Deborah Schrag, MD, MPH
Deborah Schrag, MD, MPH, Professor of Medicine at Harvard Medical School, Boston, and an oncologist at Dana-Farber Cancer Institute, commented on the findings for The ASCO Post. She said the inferior survival of patients with right-sided tumors “is almost certainly because of the molecular...
Site of Tumor Impacts Survival and Choice of Treatment in Metastatic Colorectal Cancer
In metastatic colorectal cancer, the anatomic location of the tumor within the colon appears to make a difference in overall survival as well as response to pivotal treatments, according to a retrospective analysis of the pivotal CALGB/SWOG 80405 (Alliance) trial.1 “While previous studies had...
Liquid Biopsy–Based Test Appears Comparable to Standard Tissue Testing in Detecting BRAF V600 Mutations
Cell-free (cf) DNA from plasma offers a minimally invasive approach to obtain material for BRAF mutation analysis for diagnostics and response monitoring. A study by Janku et al investigating whether the detection of BRAF V600 mutations in plasma cfDNA from patients with advanced cancers using the...
French Trial Shows Benefit of Adding Short-Term Hormone Therapy to Salvage Radiotherapy for Rising PSA After Prostatectomy
In the phase III GETUG-AFU 16 trial reported in The Lancet Oncology, Carrie et al found that adding short-term androgen suppression therapy to salvage radiotherapy was associated with improved biochemical or clinical progression-free survival among patients with prostate cancer who exhibited rising ...
Characterization of Molecular Differences in Cancer Between Male and Female Patients
It is well known that men and women differ in terms of cancer susceptibility, survival, and mortality, but exactly why this occurs at a molecular level has been poorly understood. A study at The University of Texas MD Anderson Cancer Center reviewed 13 cancer types and provided a molecular...
Use of Complementary and Alternative Medicine Affects Breast Cancer Chemotherapy Initiation
Women with early-stage breast cancer for whom chemotherapy was indicated and who used dietary supplements and multiple types of complementary and alternative medicine were less likely to start chemotherapy than nonusers of alternative therapies, according to research led by Heather Greenlee, ND,...
T-Cell Bim Levels May Reflect Responses to Anti–PD-1 Cancer Therapy
A protein called Bim may hold the clue to which patients may be successful on immunotherapy for metastatic melanoma, according to the results of a study by Mayo Clinic researchers led by senior author Haidong Dong, MD, PhD, and published by Dronca et al in JCI Insight. “Immune checkpoint...
ASCO 2016: Autologous Stem Cell Transplant Remains Relevant in Multiple Myeloma, Even in Era of Novel Agents
Early findings from a phase III clinical trial (EMN02/HO95 MM) showed that patients with multiple myeloma who received an autologous stem cell transplant survived longer without disease progression than those who received only chemotherapy using novel agents. This is the largest study reported to...
ASCO 2016: Precision Medicine Yields Better Outcomes for Patients in Phase I Clinical Trials
A meta-analysis of 346 phase I clinical trials involving more than 13,000 patients found that patients whose treatment was selected based on the molecular characteristics of their tumor had significantly better outcomes. The study was featured in a press briefing today and will be presented by...
ASCO 2016: Early Palliative Care Provides Benefits for Family Caregivers of Patients With Cancer
A randomized clinical trial found that introducing palliative care shortly after a cancer diagnosis results in better quality of life and fewer symptoms of depression among family caregivers. According to the authors, the study is the first to show that early palliative care alone for a...
ASCO 2016: PD-1 Inhibitor Pembrolizumab Provides Long-Term Survival Benefit for Patients With Advanced Melanoma in KEYNOTE-001
Long-term follow-up from a phase Ib trial (KEYNOTE-001) in newly diagnosed and previously treated patients with advanced melanoma showed that 40% of patients were alive 3 years after starting the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keytruda), with similar 36-month...
ASCO 2016: Left- vs Right-Sided Primary Tumor Location Predicts Survival in Metastatic Colorectal Cancer
For a longer-form examination of these data, click here. A retrospective analysis from a large, federally funded clinical trial finds that the location of the primary tumor within the colon predicts survival and may help inform optimal treatment selection for patients with metastatic colorectal...
AATS 2016: Stage IIIA NSCLC Survival Rates Improved When Care Included Four Specific Quality Measures
Current guidelines from the National Comprehensive Cancer Network (NCCN) and American College of Chest Physicians (ACCP) recommend that operable patients with clinical stage IIIA non–small cell lung cancer (NSCLC) should receive induction chemotherapy (with or without concurrent radiotherapy) ...
ATS 2016: Untreated Severe Obstructive Sleep Apnea Associated With Increased Aggressiveness of Cutaneous Melanoma
Untreated severe obstructive sleep apnea is associated with increased aggressiveness of malignant cutaneous melanoma, according a multicenter, prospective study. The new study, which involved researchers from 24 teaching hospitals that are part of the Spanish Sleep and Breathing Network, was...
Addition of Ixazomib to Lenalidomide/Dexamethasone Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma
Moreau et al found that adding the oral proteasome inhibitor ixazomib (Ninlaro) to lenalidomide (Revlimid) and dexamethasone significantly prolonged progression-free survival among patients with relapsed, refractory, or relapsed and refractory multiple myeloma. They reported the findings from the...
American Cancer Society Report Assesses Progress Against Goals Set for Nation 25 Years Ago
A new report assesses how the nation fared against the ambitious goal set by the American Cancer Society (ACS) to reduce cancer death rates by 50% over 25 years ending in 2015. The report finds areas where progress was substantial, and others where it was not. Published by Byers et al in CA: A ...
FDA Grants Selumetinib Orphan Drug Designation for Adjuvant Treatment of Differentiated Thyroid Cancer
AstraZeneca announced on May 12 that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for the investigational MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer. Differentiated...
AUA 2016: IsoPSA, a Novel, Structure-Based Biomarker Test for Prostate Cancer, Explored in a Multicenter Prospective Trial
A promising new test is detecting prostate cancer more precisely than current tests by identifying molecular changes in the prostate-specific antigen (PSA) protein, according to Cleveland Clinic research presented at the 111th Annual Scientific Meeting of the American Urological Association (AUA)...
Women With Breast Cancer Who Are Knowledgeable About Their Tumor Characteristics Are More Likely to Receive Guideline-Recommended Treatment
Women with breast cancer who know the characteristics of their tumor are more likely to receive the treatment recommended for their type of cancer, Dana-Farber Cancer Institute investigators reported in a new study. The study, published by Freedman et al in the Journal of Oncology Practice, is...
